Clinical Pipeline

Below is our pipeline of investigational compounds that are currently in various stages of clinical development.

For more information on the pipeline of investigational compounds generated by Astex that are currently in clinical development at Taiho Oncology Inc., please follow the link here

For more information on the pipeline of products being developed globally at Otsuka, please follow the link here

Phase 1Phase 2Phase 3

Tolinapant (ASTX660)

Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (Solid Tumors & Lymphomas)

..

ASTX029

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)

.

ASTX295

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)

.